Sevasemten 3 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, none of which are currently recruiting. The lead sponsor is Edgewise Therapeutics, Inc.. Registered phase: Phase 2. Conditions studied include Duchenne Muscular Dystrophy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05540860 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (ClinicalTrials.gov ↗) Duchenne Muscular Dystrophy |
Phase 2 | Active, closed |
| NCT06100887 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (ClinicalTrials.gov ↗) Duchenne Muscular Dystrophy |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Duchenne Muscular Dystrophy | 2 |
| Lead sponsor | Trials |
|---|---|
| Edgewise Therapeutics, Inc. | 2 |
| Register | Sevasemten 3 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sevasemten 3 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sevasemten 3 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.